Dataset

DZNE-2025-00817

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Dataset: Plasma proteomics of mice treated with BACE inhibitors

Müller, S. A.DZNE* ; Lichtenthaler, S.DZNE*

2024
PRoteomics IDEntifications Database

Abstract: The Beta-secretase BACE1 is a central drug target for Alzheimer’s disease. Clinically tested, BACE1-directed inhibitors also block the homologous protease BACE2. Yet, little is known about physiological BACE2 substrates and functions in vivo. To discover potential BAC2 substrates in plasma, mice were treated with a non-specific BACE inhibitor (Cpd89) and a BACE1 preferring inhibitor (LY2811376). Plasma proteomics using DIA showed a reduced abundance of soluble FLT4 (sVEGFR3) for the non-specific inhbtor but not for the BACE1 preferring inhibitor. Conclusively, sVEGFR3 is a potential marker for BACE2 inhibition in plasma.

---

Contributing Institute(s):

1. Neuroproteomics (AG Lichtenthaler)

Research Program(s):

1. 352 - Disease Mechanisms (POF4-352) (POF4-352)

---

---

Linked articles:

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article Schmidt, A. (First author)DZNE* ; Hrupka, B. ; van Bebber, F.DZNE* ; Sunil Kumar, S. ; Feng, X.DZNE* ; Tschirner, S. K.DZNE* ; Aßfalg, M.DZNE* ; Müller, S. A.DZNE* ; Hilger, L. S.DZNE* ; Hofmann, L. I.DZNE* ; Pigoni, M.DZNE* ; Jocher, G.DZNE* ; Voytyuk, I. ; Self, E. L. ; Ito, M. ; Hyakkoku, K. ; Yoshimura, A. ; Horiguchi, N. ; Feederle, R.DZNE* ; De Strooper, B. ; Schulte-Merker, S. ; Lammert, E. ; Moechars, D. ; Schmid, B.DZNE* ; Lichtenthaler, S. F. (Last author)DZNE*
The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling.
The journal of clinical investigation 134(16), e170550 (2024) [10.1172/JCI170550]2024   Files  Fulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS

---